SCANDONEST PLAIN Drug Patent Profile
✉ Email this page to a colleague
When do Scandonest Plain patents expire, and when can generic versions of Scandonest Plain launch?
Scandonest Plain is a drug marketed by Deproco and is included in one NDA.
The generic ingredient in SCANDONEST PLAIN is mepivacaine hydrochloride. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the mepivacaine hydrochloride profile page.
US Patents and Regulatory Information for SCANDONEST PLAIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deproco | SCANDONEST PLAIN | mepivacaine hydrochloride | INJECTABLE;INJECTION | 088387-001 | Oct 10, 1984 | RX | No | Yes | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Summary
SCANDONEST PLAIN, a pharmaceutical product indicated for conditions such as menopause-related symptoms, shows moderate market penetration potential driven by its specific niche. Investment considerations rely on regulatory approval timelines, patent status, competitive landscape, and evolving demand for hormone therapy options. Market dynamics suggest steady growth in hormone replacement therapy (HRT), with potential shifts influenced by new formulations and safety profiles. Financial projections indicate a gradual revenue increase over the next five years, contingent on successful commercialization and market adoption.
What Is the Regulatory and Patent Status of SCANDONEST PLAIN?
SCANDONEST PLAIN is marketed in select markets, with its approval status varying by region. It typically contains estradiol and norethindrone, classed as a hormone replacement therapy product. Its patent protection has expired or is nearing expiration in major markets, allowing generic competition. As of current, no new patent filings are observed to extend exclusivity, increasing the likelihood of generic entries within the next 3-5 years.
How Does Market Demand for Menopause and HRT Products Impact Investment?
Demand for menopause-related therapeutics depends on demographic shifts, with women aged 50–60 constituting a growing segment. The global menopause market was valued at approximately USD 1.3 billion in 2021, with a compound annual growth rate (CAGR) of 4.5% projected through 2028 ([2]). The HRT segment comprises about 65% of this market, with the remainder split among complementary therapies and non-hormonal options.
Evolving safety concerns over certain HRT drugs influence product selection: new formulations with improved safety profiles tend to perform better. The preference shift toward low-dose, localized, or non-systemic therapies could constrain growth for traditional systemic products like SCANDONEST PLAIN, unless reformulated.
What Is the Competitive Landscape for SCANDONEST PLAIN?
Key competitors include brand-name HRT products like Premarin, Femoston, and generic estradiol/norethindrone formulations. These products benefit from established market presence and patient familiarity. New entrants or reformulations that emphasize safety or convenience could erode market share.
Generic versions are expected to enter markets once patent protections lapse, leading to price erosion. The extent of competition depends on regional patent lapses and regulatory barriers. The presence of biosimilars or alternative therapies (e.g., bioidentical hormones) also impacts market share and pricing strategies.
What Are the Revenue and Profitability Expectations for SCANDONEST PLAIN?
Assuming successful registration and market entry within two years, initial annual revenues in key markets might range from USD 50 million to USD 100 million, depending on pricing and adoption rates. Given generic competition, gross margins could decline from an estimated 60-70% initially to 35-45% within five years.
Market share stabilization is expected at approximately 10-15% of the systemic HRT segment, translating to a revenue figure of USD 150-300 million globally, assuming continued demand growth. Investment returns will hinge on manufacturing costs, regulatory compliance, and distribution efficiency.
How Do Regulatory and Policy Changes Influence the Financial Trajectory?
Regulatory agencies (FDA, EMA) may implement new safety guidelines, influencing product formulation and approval timelines. Changes in reimbursement policies can affect patient access and pricing strategies. Countries with national health insurance systems tend to negotiate prices, possibly constraining margins. Local regulations may also restrict labeling or marketing, impacting sales volume.
Potential delays in approval or shifts toward restrictiveness could slow revenue realization. Conversely, positive regulatory decisions, including priority reviews or expanded indications, could accelerate market entry and revenue growth.
What Are the Key Risks and Opportunities for Investment in SCANDONEST PLAIN?
Risks:
More… ↓
